Impact of Residual Endotoxin in Plasmid DNA on Downstream Applications and Removal Validation

Why downstream applications need to pay attention to residual endotoxin

Plasmid DNA is widely used in transfection, viral vector packaging, mRNA template preparation, and cell and gene therapy-related research. Endotoxin (lipopolysaccharide) can induce cellular inflammatory responses, affect cell status, and even interfere with transfection expression. Although different cell types vary in their sensitivity to endotoxin, for result reproducibility and biosafety, it is usually necessary to remove endotoxin from plasmid DNA as much as possible during the plasmid preparation stage.

Removal technologies and validation approaches

Ion exchange, hydrophobic chromatography, affinity adsorption, two-phase extraction, and other methods can be used to remove endotoxin from plasmid DNA. Validation approaches generally include:

Pre-process assessment: measure the endotoxin level in the crude extract sample and clarify the properties of the main impurities to be removed.

Stepwise sampling: sample and test before and after key purification steps to determine the contribution of each unit operation to removal.

Repeated batch investigation: pay attention to the consistency of removal effects among different batches.

Comparison with finished product standards: compare test results with the acceptable limits preset for the project.

For detection methods, the Limulus amebocyte lysate assay or recombinant factor C method can be used, taking care to eliminate interference. Because endotoxin may exist as aggregates, the retention effect of filtration or chromatography may be affected by buffer conditions, and different scales and storage conditions should be considered during validation.

Quality standards and compliance recommendations

As a biological reagent or raw material, the endotoxin control level of plasmid DNA usually needs to match its final use. General requirements are often expressed as endotoxin units corresponding to plasmid DNA per unit mass, but the specific limit should be comprehensively set according to product type, route of administration, and regulatory guidelines. When establishing quality standards, relevant companies can refer to the ideas on bacterial endotoxin testing in pharmacopoeias and industry guidelines, and combine their own process capabilities and stability data to form reasonable release specifications.

Attention should also be paid to documentation and traceability: from bacterial strain, fermentation, lysis, and purification to finished product storage, changes in each step may affect residual endotoxin. Through continuous monitoring and trend analysis, it is helpful to more stably remove endotoxin from plasmid DNA and reduce batch-to-batch differences.

Conclusion

Control of residual endotoxin is an important part of the safety and quality of plasmid DNA downstream applications. Establishing a scientific removal and validation system not only helps meet research needs, but also lays the foundation for subsequent translation and compliance filing.